Your browser doesn't support javascript.
loading
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
Suh, N; Wang, Y; Williams, C R; Risingsong, R; Gilmer, T; Willson, T M; Sporn, M B.
Affiliation
  • Suh N; Department of Pharmacology and Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Cancer Res ; 59(22): 5671-3, 1999 Nov 15.
Article in En | MEDLINE | ID: mdl-10582681
ABSTRACT
We have tested a new ligand for peroxisome proliferator-activated receptor-gamma, GW7845, as an inhibitor of experimental mammary carcinogenesis, using the classic rat model with nitrosomethylurea as carcinogen. Rats were first treated with a single dose of nitrosomethylurea (50 mg/kg body weight, i.p.). Starting 1 week later, they were fed GW7845, at either 60 or 30 mg/kg of diet, for 2 months. This agent significantly reduced tumor incidence, tumor number, and tumor weight at both doses. This is the first report of the use of a ligand for peroxisome proliferator-activated receptor-gamma to prevent experimental breast cancer.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Tyrosine / Transcription Factors / Anticarcinogenic Agents / Receptors, Cytoplasmic and Nuclear / Mammary Neoplasms, Experimental Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Res Year: 1999 Document type: Article Affiliation country: Estados Unidos
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Tyrosine / Transcription Factors / Anticarcinogenic Agents / Receptors, Cytoplasmic and Nuclear / Mammary Neoplasms, Experimental Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Res Year: 1999 Document type: Article Affiliation country: Estados Unidos
...